Rate My Professor Jeffrey Fineman

Dr. Fineman's research focuses on pulmonary hypertension in children, encompassing persistent pulmonary hypertension of the newborn, pulmonary arterial hypertension, and vascular diseases associated with congenital heart disease. His NIH-funded laboratory employs integrated physiologic, biochemical, molecular, and anatomic approaches, utilizing fetal surgical techniques to create ovine models that mimic congenital heart disease with increased pulmonary blood flow. Key investigations include endothelial dysfunction, nitric oxide and endothelin-1 signaling, mechanotransduction, metabolic reprogramming, mitochondrial dynamics, oxidative stress, and bioenergetics in pulmonary vasculature. His contributions have advanced therapies such as inhaled nitric oxide, approved by the FDA for persistent pulmonary hypertension of the newborn. Dr. Fineman has published over 260 peer-reviewed articles, with more than 12,000 citations. Notable works include 'Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society' (Circulation, 2015), 'Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry' (European Respiratory Journal, 2022), 'Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia' (Journal of Pediatrics, 2017), and 'Pulmonary Vascular Endothelial Dysfunction Is Induced by Nonpulsatile Pulmonary Blood Flow in an Ovine Classic Glenn Model' (Comprehensive Physiology, 2025). He leads clinical trials evaluating pulmonary vasodilators like treprostinil, macitentan, and selexipag in pediatric pulmonary arterial hypertension and contributes to the PPHNet-BOLD biospecimen registry. In 2016, he received the UCSF Department of Pediatrics FLAG Mentorship Award. In 2021, he completed UCSF Diversity, Equity, and Inclusion Champion Training.